[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 47 of about 47
1. Burnei G, Burnei C, Hodorogea D, Gavriliu S, Georgescu I, Vlad C: Osteoarticular reconstructive surgery in malignant bone tumors: the importance of external fixators. J Med Life; 2008 Jul-Sep;1(3):295-306
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients with malignant bone tumors (table 1.) were studied by sex, tumor type, location, age at the moment of diagnosis, age at the moment of the last evaluation, type of surgery, external fixator implanted, complications, results and survival period.
  • We also considered for each patient the extent of the tumor to diaphysis, soft tissue involvement, involvement of physis and epiphyseal invasion, articular extent, vessels and nerves invasion, presence of metastases and local skin invasion.
  • The certain diagnosis was based on pathological anatomy exam, because clinical and imagistic data were not decisive in each case.
  • The postoperative complications were not fatal.
  • Only two patients, who have survived 6 months and respectively 18 months, were not able to return to prior activities.
  • The other six were reinserted in social activities.
  • The conservative treatment is preferred to the amputation, which is being used in very few cases.
  • The development of reconstructive bone surgery is sustained by the possibility to delineate the tumor by diagnosis based on imaging and by the possibility to use modern preoperative and postoperative chemotherapy and radiotherapy.
  • Limb conservation was possible only in aggressive benign tumors up to 1970.
  • Since then the same treatment was preferred also in malignant bone tumors, because the relapse appeared as frequent as in cases with amputation but the physical and psychological comfort made the patients to accept it readily.
  • The goal of malignant bone tumors treatment is to save the life of the patient, to preserve the affected limb, to maintain the length and function of the limb.
  • Oncologic surgery consists of "en bloc" tumor resection followed by bone reconstruction or modular prosthetic replacement.
  • Modular prosthetic replacement leads to the loss of at least one growing cartilage.
  • The use of radiotherapy in some cases may also affect other growing cartilages, leading to limb length discrepancies.
  • [MeSH-major] Bone Neoplasms / surgery. Chondrosarcoma / surgery. External Fixators. Giant Cell Tumor of Bone / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Fatal Outcome. Female. Femur / surgery. Humans. Humerus / surgery. Male. Reconstructive Surgical Procedures / methods. Retrospective Studies. Sarcoma, Ewing / surgery. Tibia / surgery. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Orthop. 1987;11(1):35-41 [3549587.001]
  • [Cites] Clin Orthop Relat Res. 2000 Apr;(373):51-61 [10810462.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1985;71(7):435-50 [3911313.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] J Bone Joint Surg Br. 1995 Jul;77(4):608-14 [7615607.001]
  • [Cites] Ital J Orthop Traumatol. 1975 Apr;1(1):5-22 [1067250.001]
  • [Cites] J Bone Joint Surg Am. 1988 Apr;70(4):507-16 [3281952.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jul;79(4):558-61 [9250738.001]
  • [Cites] J Bone Joint Surg Am. 1990 Mar;72(3):334-45 [2135632.001]
  • [Cites] Clin Orthop Relat Res. 2001 Sep;(390):212-20 [11550868.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):181-96 [1884538.001]
  • [Cites] Int Orthop. 1998;22(1):27-31 [9549578.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1393-9 [4045528.001]
  • [Cites] Int Orthop. 1988;12(1):21-9 [3372098.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] J Bone Joint Surg Am. 1978 Jan;60(1):31-40 [415064.001]
  • [Cites] Acta Orthop Scand. 1989 Apr;60(2):143-53 [2658466.001]
  • [Cites] Int Orthop. 1998;22(5):330-4 [9914940.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • (PMID = 20108507.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


2. Loubignac F, Bourtoul C, Chapel F: Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance. World J Surg Oncol; 2009;7:42
Genetic Alliance. consumer health - Myxoid liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance.
  • BACKGROUND: Lipoma is by far the most common of all benign soft-tissue tumors which far outnumber malignant tumors.
  • Soft-tissue sarcomas are malignant tumors and are usually named for the type of tissue in which they begin.
  • Liposarcoma (LPS), which arises in the fatty tissue, is rather an uncommon soft-tissue tumor.
  • In two-third of the cases, this tumor occurs in the muscle while often demonstrating a misleading benign appearance as observed in the majority of soft-tissue sarcomas.
  • CASE PRESENTATION: We report the case of a 50-year-old man operated on for a fat tumor of the thigh initially diagnosed as lipoma but revealing to be a myxoid liposarcoma after histopathological examination.
  • The initial incomplete tumor excision required the need for a re-excision with adjuvant chemotherapy and complementary radiotherapy.
  • CONCLUSION: When any suspicious soft-tissue tumor is diagnosed, the combined information gathered from accurate preoperative radiographic planning and X-rays or surgical biopsy is of tremendous value for establishing the most appropriate therapeutic program, highly adapted to the histopathological findings.
  • [MeSH-minor] Biopsy. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pathol. 1998 Dec;18(6):505-11 [10051921.001]
  • [Cites] Ann Pathol. 1998 Dec;18(6):473-80 [10051914.001]
  • [Cites] Ann Pathol. 1998;18(5 Suppl):59-63 [9884758.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Apr;17(2):130 [15830582.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2006 Nov;92(7):637-50 [17124447.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1450-8 [8608528.001]
  • (PMID = 19386100.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2678127
  •  go-up   go-down


3. Miettinen M, Kraszewska E, Sobin LH, Lasota J: A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer; 2008 Feb 1;112(3):645-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia.
  • BACKGROUND: Gastrointestinal stromal tumors (GISTs) are KIT-positive mesenchymal tumors of the gastrointestinal tract that are driven by activated KIT-signalling or platelet-derived growth factor receptor-alpha (PDFGRA) signaling.
  • These tumors most commonly occur in the stomach and small intestine and encompass a clinical spectrum from benign to malignant.
  • BACKGROUND: Nine patients (2 with gastric GISTs and 7 with GISTs of the small intestine) developed myeloid leukemia.
  • There were 6 patients (4 women and 2 men) with acute myeloid leukemia (AML), including 1 case of promyelocytic and 1 case of myelomonocytic leukemia, and 3 patients (2 men and 1 woman) with chronic myeloid leukemia (CML).
  • RESULTS: The leukemias developed 1.7 to 21 years after the GIST (median interval, 6 years).
  • None of the GIST patients had received radiotherapy or chemotherapy prior to the leukemia diagnosis.
  • All but 1 GIST case was found to have a low mitotic rate (0-1 per 50 high-power fields); however, tumor size varied from 3 to 18 cm (median, 4.5 cm).
  • There was a slightly increased risk for CML, but this was not statistically significant (SIR of 3.71; 95% CI, 0.7-9.1).
  • CONCLUSIONS: Additional epidemiologic, clinical, and pathogenetic studies are needed to understand the apparent nonrandom association between GIST and myeloid leukemia.
  • [MeSH-major] Gastrointestinal Stromal Tumors / epidemiology. Intestinal Neoplasms / epidemiology. Leukemia, Myeloid / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Incidence. Longitudinal Studies. Male. Middle Aged. Prognosis. Risk Factors


Advertisement
4. Dalloul M, Sherer DM, Gorelick C, Serur E, Zinn H, Sanmugarajah J, Zigalo A, Abulafia O: Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma. Ultrasound Obstet Gynecol; 2007 Feb;29(2):236-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma.
  • Bilateral ovarian enlargement may reflect benign or malignant processes of the ovary.
  • Benign causes of ovarian enlargement include luteomas, tumors such as mature cystic teratomas, fibrothecomas, cystadenomas and rare conditions including capillary hemangioma and massive edema of the ovaries.
  • Primary malignancies that may exhibit metastases to the ovaries include gastrointestinal, breast and soft tissue tumors such as lymphoma.
  • We present an unusual case in which a patient presenting with weakness and mild lower abdominal and pelvic pain was noted at sonography to have bilaterally enlarged ovaries with features similar to those of massive ovarian edema as described previously, which has been associated with venous and lymphatic obstruction.
  • Subsequent computerized tomography (CT) imaging depicted a large retroperitoneal tumor, CT-guided biopsy of which revealed diffuse large B cell lymphoma.
  • The patient responded well to chemotherapy with significant shrinkage of the tumor, and reappearance of normal findings on ovarian sonography.
  • This case demonstrates that bilaterally enlarged ovaries may be the first clinical evidence of a large retroperitoneal tumor and that in such cases CT imaging may be warranted.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Ovarian Neoplasms / pathology. Ovary / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Hypertrophy / etiology. Hypertrophy / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 17252529.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Maurel J, Buesa J, López-Pousa A, del Muro XG, Quintana MJ, Martín J, Casado A, Martínez-Trufero J, de Las Peñas R, Balañá C: Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS). J Surg Oncol; 2004 Oct 1;88(1):44-9
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).
  • PURPOSE: To assess the impact of different factors on response rate (RR), time to tumor progression (TTP), and overall survival time (OS) in patients with locally advanced or metastatic soft tissue sarcoma (ASTS), included in three protocols with high-dose ifosfamide (HDIF).
  • PATIENTS AND METHODS: One hundred fifty six ASTS patients included in three consecutive phase II trials with HDIF (>10 g/m(2)), alone or in combination with doxorubicin (DX), were analyzed.
  • Cofactors were institution, trial, gender, age, performance status, histologic type, grade of malignancy, prior radiotherapy, presence of locoregional disease, metastatic site, salvage surgery, number of organs involved, and disease-free interval.
  • RESULTS: By multivariate analysis performance status >0 and lack of salvage surgery correlated with a poorer survival.
  • A good-risk and a poor-risk group were identified, with median survival time (OS) of 29, 5, and 10 months, respectively (P = 0.00001).
  • The 1-, 2-, and 3-year OS for 83 good-risk patients (either with PS = 0 or receiving salvage surgery) was 83, 44, and 29%, respectively, those figures being 37, 7, and 3% for 73 poor-risk patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Clinical Trials, Phase II as Topic. Ifosfamide / administration & dosage. Patient Selection. Salvage Therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Bias (Epidemiology). Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Fibrosarcoma / drug therapy. Fibrosarcoma / mortality. Fibrosarcoma / pathology. Fibrosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / mortality. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / drug therapy. Liposarcoma / mortality. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neurofibrosarcoma / drug therapy. Neurofibrosarcoma / mortality. Neurofibrosarcoma / pathology. Neurofibrosarcoma / surgery. Proportional Hazards Models. Research Design. Spain. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15384088.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


6. Sangiorgi L, Gobbi GA, Lucarelli E, Sartorio SM, Mordenti M, Ghedini I, Maini V, Scrimieri F, Reggiani M, Bertoja AZ, Benassi MS, Picci P: Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer; 2001 May 20;95(3):156-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness.
  • Telomerase activity was observed and correlated with aggressiveness in different neoplasms such as breast, prostate, blood and brain cancers, among others.
  • To investigate whether telomerase activity is an index of aggressiveness in bone and soft tissue lesions of the extremities, 66 biopsy samples from our tissue bank were studied.
  • These samples included 43 high-grade sarcomas, 9 aggressive benign tumors and 14 totally benign lesions.
  • The samples were collected from patients homogeneously treated at the Rizzoli Orthopaedic Institute with a follow-up ranging from 4 to 11 years (median, 7 years).
  • All tumors investigated were positive for telomerase activity.
  • Among benign lesions, only 2 aneurysmal bone cysts showed higher telomerase activity than the cut-off point, whereas all the other benign lesions had lower activity.
  • Our results indicate that high levels of telomerase activity in bone and soft tissue lesions correlate with more aggressive clinical behavior in patients treated with surgery alone.
  • An interesting inverse correlation between telomerase activity and occurrence of pulmonary metastasis was detected in osteosarcoma patients treated with chemotherapy.
  • A parallel increase of telomerase activity and malignancy was observed in the adipose and cartilagineous tissue lesions.
  • Our data suggest that telomerase activity could be considered a marker of tumor aggressiveness for bone and soft tissue lesions.
  • The results obtained in osteosarcoma samples suggest that low levels of telomerase activity may be predictive of the prognosis and should influence the therapeutic protocol.
  • [MeSH-major] Bone Neoplasms / enzymology. Soft Tissue Neoplasms / enzymology. Telomerase / metabolism
  • [MeSH-minor] Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11307148.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


7. Vukasinović Z, Spasovski D, Slavković N, Slavković S, Zivković Z: [Chondroblastoma--current opinion]. Srp Arh Celok Lek; 2006 Nov-Dec;134(11-12):567-70
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondroblastoma of bone is rare bone tumor, representing around 1% of benign bone lesions.
  • It is considered a benign lesion, although primary malignant form as well as malignant alteration in the form of chondrosarcoma has been documented.
  • It occurs predominantly in the second decade, more commonly in males.
  • Predilection sites include proximal humeral epiphysis, femoral and tibial condyles, but it can be found in other bones, too (skull, pelvis, posterior vertebral structures, tarsal bones).
  • Pathohistologically, it is described as highly cellular tissue, variably differentiated and with discrete granulated to meshy calcification of the matrix and large multinuclear cells present in 20% of cases.
  • Tumor is presented with a few nonspecific local symptoms, which makes diagnostic procedure more difficult.
  • Definitive diagnosis is made only by pathohistological verification.
  • The treatment of chondroblastoma is strictly surgical, with a view to counteract the propagation into the joint or adjacent soft tissue, and diminish the recurrence rate.
  • Chemotherapy is not indicated for treatment of this tumor, and radiotherapy is contraindicated as it stimulates malignant alteration.
  • If malignant chondroblastoma of bone is verified pathohistologically, radical treatment by surgical resection is indicated, also avoiding any adjuvant therapy.
  • [MeSH-major] Bone Neoplasms. Chondroblastoma

  • Genetic Alliance. consumer health - Chondroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304775.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia and Montenegro
  • [Number-of-references] 34
  •  go-up   go-down


8. Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A: EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol; 2009 Oct;22(10):1328-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.
  • To gain the insight into the involvement of signaling mediated by the mammalian target of rapamycin (mTOR) in the phenotype and biological profiles of tumors and tumor-like lesions of the bone and soft tissue, we analyzed the expression and phosphorylation (activation) of mTOR and its correlation with the status of upstream and downstream modulator proteins Akt, p70S6-kinase (S6K), and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), which we refer to collectively as mTOR cassette proteins.
  • Immunohistochemical analysis of 140 cases showed activation of Akt in 55% (61% in malignant and 27% in benign), and mTOR expression in 61% (66% in malignant and 39% in benign).
  • The preponderance of mTOR activation was found in tumors of peripheral nerve sheath (malignant peripheral nerve sheath tumor and schwannoma), skeletal muscle origin (rhabdomyosarcoma), and in those exhibiting epithelial nature (chordoma and synovial sarcoma).
  • Together with the result of immunoblotting analysis, it was shown that many of those particular tumors with mTOR activation exhibited activation of Akt, S6K, and 4E-BP1, suggesting the constitutive activation of the Akt/mTOR pathway.
  • By clinicopathological analysis, activation of Akt correlates with statistically higher probability of metastasis.
  • We conclude that mTOR-mediated signaling proteins function not only in the proliferation of the tumor cells, but also in the differentiation and/or maintenance of morphological phenotypes in tumors of rhabdomyoblastic and nerve sheath cell origin.
  • Additionally, activated Akt may have a function in metastasis.
  • Overall, these results suggest that inhibitors of mTOR cassette may be useful as novel components of combined chemotherapy for a defined subset of bone and soft tissue sarcomas.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Bone Neoplasms / enzymology. Phosphoproteins / analysis. Protein Kinases / analysis. Proto-Oncogene Proteins c-akt / analysis. Receptor, Epidermal Growth Factor / analysis. Ribosomal Protein S6 Kinases, 70-kDa / analysis. Signal Transduction. Soft Tissue Neoplasms / enzymology
  • [MeSH-minor] Cell Proliferation. Enzyme Activation. Humans. Immunoblotting. Immunohistochemistry. Mutation. Neoplasm Staging. Phosphorylation. Prognosis. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648884.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  •  go-up   go-down


9. Minard-Colin V, Orbach D, Martelli H, Bodemer C, Oberlin O: [Soft tissue tumors in neonates]. Arch Pediatr; 2009 Jul;16(7):1039-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue tumors in neonates].
  • [Transliterated title] Les tumeurs mésenchymateuses du nouveau-né.
  • Soft tissue tumors account for approximately 25% of neonatal tumors and are most often benign (more than 2/3 of cases).
  • Vascular tumors are the most frequent benign tumors and infantile hemangioma accounts for 32% of these tumors, affecting 1 out of 200 children at birth.
  • Kaposiform hemangioendothelioma (KH) is a rare vascular tumor with locally aggressive behavior.
  • More than 50% of KH are associated with the Kasabach-Merritt phenomenon, a condition characterized by thrombocytopenia and consumptive coagulopathy.
  • Malignant soft tissue tumors are, after neuroblastoma, the second cause of cancer in neonates.
  • Infantile fibrosarcoma (IF) is a rare tumor that most often affects the extremities of children aged 4 years or younger.
  • Chemotherapy is indicated when initial surgical removal cannot be accomplished without unacceptable morbidity.
  • Neonatal rhabdomyosarcoma (RMS) is a rare tumor (0.5-1% of RMS).
  • The primary tumor predominantly involves the limbs and the genitourinary tract.
  • Treatment is based on age-adapted chemotherapy and surgery.
  • [MeSH-major] Soft Tissue Neoplasms / congenital
  • [MeSH-minor] Fibrosarcoma / congenital. Fibrosarcoma / diagnosis. Fibrosarcoma / genetics. Fibrosarcoma / therapy. Gene Fusion / genetics. Gene Rearrangement / genetics. Hemangioendothelioma / congenital. Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Hemangioma / congenital. Hemangioma / diagnosis. Hemangioma / therapy. Humans. Infant, Newborn. Prognosis. Proto-Oncogene Proteins c-ets / genetics. Receptor, trkC / genetics. Repressor Proteins / genetics. Rhabdomyosarcoma / congenital. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398311.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; EC 2.7.10.1 / Receptor, trkC
  • [Number-of-references] 37
  •  go-up   go-down


10. Fritz MA, Sade B, Bauer TW, Wood BG, Lee JH: Benign fibrous histiocytoma of the pterygopalatine fossa with intracranial extension. Acta Neurochir (Wien); 2006 Jan;148(1):73-6; discussion 76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign fibrous histiocytoma of the pterygopalatine fossa with intracranial extension.
  • A very rare case of fibrous histiocytoma arising in the pterygopalatine fossa with intracranial extension is described.
  • Despite the histologic absence of nuclear pleomorphism, the tumor rapidly recurred after complete surgical resection.
  • The patient, a 45 year old male, died shortly thereafter.
  • The aggressive nature of our patient's tumor confirms previous observations that an aggressive radiographic appearance has prognostic value when dealing with skeletal and soft tissue tumors.
  • The benefit of multimodal therapy has not been established in these rare head and neck lesions.
  • In the subset of fibrous histiocytomas that invade bone, however adjunctive treatment with radiation and or chemotherapy may be appropriate.
  • [MeSH-major] Brain / pathology. Histiocytoma, Benign Fibrous / pathology. Neoplasm Recurrence, Local / pathology. Palate, Hard. Skull Base Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200478.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


11. Kurosawa H, Matsunaga T, Shimaoka H, Sato Y, Kuwashima S, Sugita K, Hagane K, Eguchi M: Burkitt lymphoma associated with large gastric folds, pancreatic involvement, and biliary tract obstruction. J Pediatr Hematol Oncol; 2002 May;24(4):310-2
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma associated with large gastric folds, pancreatic involvement, and biliary tract obstruction.
  • Large gastric folds in adults are seen in many benign and malignant conditions, but they are rare in children with malignant diseases such as non-Hodgkin lymphoma.
  • A 14-year-old boy was referred to the authors' hospital with upper abdominal pain and jaundice.
  • A standard barium upper gastrointestinal series showed large gastric folds in the entire stomach.
  • Magnetic resonance imaging showed a typical diffuse infiltrating type of pancreatic lymphoma.
  • Because complete bilateral lower limb paralysis developed as a result of the epidural soft tissue mass, laminectomy and tumor resection were performed and a diagnosis of disseminated Burkitt lymphoma was established.
  • After completing 6 months of chemotherapy, the patient has been disease-free without neurologic complications for 2.5 years.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cholestasis / diagnosis. Gastric Mucosa / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11972102.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Rodriguez-Galindo C, Ramsey K, Jenkins JJ, Poquette CA, Kaste SC, Merchant TE, Rao BN, Pratt CB, Pappo AS: Hemangiopericytoma in children and infants. Cancer; 2000 Jan 01;88(1):198-204
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hemangiopericytoma (HPC) is a soft-tissue neoplasm most commonly seen in adults; only 5-10% of cases occur in children.
  • Infantile HPC, however, although histologically identical to adult HPC, has a more benign clinical course.
  • The reasons for these differences in the natural history of HPC are not well understood.
  • METHODS: The authors reviewed the clinicopathologic features of HPC as well as the treatment and outcomes of the 12 children (9 males and 3 females) treated for this disease at St. Jude Children's Research Hospital over a 35-year period.
  • RESULTS: At diagnosis, 9 patients were older than 1 year and 3 were younger than 1 year.
  • Among the 9 older patients, tumors were most commonly found in the lower extremities (n = 5).
  • One patient had been treated for acute lymphoblastic leukemia 15 years earlier.
  • One patient had metastatic disease at diagnosis, and three had unresectable tumors.
  • Two patients experienced objective responses to chemotherapy.
  • Three patients died of disease progression.
  • Among the three infants, two had unresectable disease at diagnosis, and both experienced excellent responses to neoadjuvant chemotherapy.
  • In one case, the response of the tumor to chemotherapy correlated with maturation to hemangioma.
  • All three infants are alive without evidence of disease.
  • CONCLUSIONS: HPC in children older than 1 year does not differ from adult HPC, and aggressive multimodality therapy is required.
  • Infantile HPC, on the other hand, is characterized by better clinical behavior, with documented chemoresponsiveness and spontaneous regression, and requires a more conservative surgical approach.
  • In some cases of infantile HPC, this benign behavior correlates with maturation to hemangioma.
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Medical Records. Neoplasm Staging. Retrospective Studies. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10618624.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / PHS HHS / / LA-23099; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


13. Perez EA, Gutierrez JC, Moffat FL Jr, Franceschi D, Livingstone AS, Spector SA, Levi JU, Sleeman D, Koniaris LG: Retroperitoneal and truncal sarcomas: prognosis depends upon type not location. Ann Surg Oncol; 2007 Mar;14(3):1114-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal and truncal sarcomas: prognosis depends upon type not location.
  • BACKGROUND: Prognostication of truncal and retroperitoneal soft tissue sarcomas has traditionally been predicated on tumor location and grade.
  • METHODS: Retrospective analysis of a prospective cancer data registry from 1977 to 2004 was performed and outcomes were determined.
  • RESULTS: The study group numbered 312 patients (median age 58 years, 54% male, 56% Caucasian, 14% black, 29% Hispanic).
  • The most common tumor types were liposarcoma (35.9%), leiomyosarcoma (30.1%), and malignant fibrous histiocytoma (MFH) (19.5%).
  • Tumor distributions were retroperitoneal (38.9%), pelvic (24.7%), abdominal (18.6%) and thoracic (17.9%).
  • Univariate analysis comparing retroperitoneal versus truncal location demonstrated no significant differences in survival.
  • Survival was improved in lower grade tumors (P < 0.02).
  • Liposarcoma and fibrosarcoma were associated with improved survival (P < 0.0001).
  • Multivariate analysis of pre-treatment variables showed increasing age, grade, histopathology (leiomyosarcoma and MFH) and metastasis to be associated with worse outcomes.
  • Multivariate analysis of the treatment variables showed that surgery and negative resection margins were associated with improved survival (P < 0.001).
  • CONCLUSIONS: Successful operative resection can confer prolonged disease-free survival and cure for truncal and retroperitoneal sarcomas.
  • Histological subtype, not location, is predictive of long-term survival.
  • Future studies should focus on histological subtype rather than tumor location for truncal and retroperitoneal sarcomas.
  • [MeSH-major] Retroperitoneal Neoplasms / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Extremities / pathology. Female. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Fibrosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / drug therapy. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206483.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Patel T, Bansal R, Trivedi P, Modi L, Shah MJ: Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):482-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report.
  • Metastasis of mesothelioma of the pleura, to the skin and subcutis is an extremely rare occurrence.
  • A 25 year old woman, who had undergone chemotherapy, partial excision of tumor followed by radiotherapy of sarcomatoid mesothelioma of the pleura, presented three months later with painless widespread subcutaneous nodules.
  • It is essential to differentiate neoplasm metastatic to the skin and subcutis from primary and benign lesions of the same region.
  • FNAC is accurate and efficient, in conjugation with clinical history, and it also prevents surgical biopsy in the diagnosis of metastatic subcutaneous lesion.
  • To our knowledge, this is the first case, reported till date, in which the sarcomatoid mesothelioma metastasized to the subcutaneous tissue and was diagnosed by fine needle aspiration cytology (FNAC).
  • [MeSH-major] Mesothelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pleural Neoplasms. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Subcutaneous Tissue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366102.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


15. Wang J, Zhu XZ, Zhang RY: [Malignant granular cell tumor: a clinicopathologic analysis of 10 cases with review of literature]. Zhonghua Bing Li Xue Za Zhi; 2004 Dec;33(6):497-502
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant granular cell tumor: a clinicopathologic analysis of 10 cases with review of literature].
  • OBJECTIVE: To investigate the clinicopathologic features of malignant granular cell tumor (MGCT) and evaluate the histologic criteria for diagnosis of malignancy.
  • METHODS: The clinical and pathologic profiles of 10 MGCT cases were evaluated.
  • Electron microscopy was carried out in 3 cases with available fresh or formalin-fixed tissues.
  • RESULTS: Four patients were males and six were females.
  • Their age ranged from 27 to 73 years (mean = 46 years).
  • The main presenting symptom was a painless nodule or mass located in the subcutis or deep soft tissue.
  • One case had peripheral nerve symptoms.
  • Three of the tumors occurred in the lower extremity, two in the breast, two in the nuchal region, and one each in the chest wall, neck, and peritoneal cavity.
  • The tumor size ranged from 2 to 11 cm (mean size = 4.8 cm).
  • Microscopically, the tumor was composed of nests or sheets of polygonal cells which possessed abundant eosinophilic granular cytoplasm and closely resembled its benign counterpart.
  • After careful assessment, 9 cases exhibited at least 3 of the following suspicious features: enlarged vesicular nuclei with prominent nucleoli, nuclear pleomorphism, high nuclear-to-cytoplasmic ratio, spindling of tumor cells, appreciable mitotic activity, and tumor necrosis.
  • In addition, a hitherto undescribed feature characterized by multinucleated tumor cells was observed in 1 case.
  • The remaining case demonstrated benign-appearing features but behaved in a malignant fashion.
  • Follow-up information available in 7 patients revealed local recurrence in 5, metastasis in 4 and tumor-related deaths in 2 patients.
  • In exceptional circumstances, however, the diagnosis relies on clinicopathologic correlation.
  • Based on the current study and literature review, a modified criterion of mitotic count (> 5/50 HPF instead of > 2/10 HPF) is recommended.
  • Wide local excision with regional lymph node dissection remains the mainstay of treatment.
  • Chemotherapy and radiotherapy however have not been shown to significantly improve the clinical course of the disease.
  • The morphologic spectrum of MGCT also includes a rare multinucleated variant.
  • [MeSH-major] Breast Neoplasms / pathology. Granular Cell Tumor / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Female. Humans. Lower Extremity. Lymph Node Excision. Male. Middle Aged. Phosphopyruvate Hydratase / metabolism. Retrospective Studies. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15634442.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 32
  •  go-up   go-down


16. Yu H, Wang CF, Yang WT, Zhu XZ: [Angiomatoid fibrous histiocytoma: report of 5 cases with review of literature]. Zhonghua Bing Li Xue Za Zhi; 2010 Apr;39(4):245-8
Genetic Alliance. consumer health - Histiocytoma, angiomatoid fibrous.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and differential diagnosis of angiomatoid fibrous histiocytoma (AFH).
  • RESULTS: There were a total of 3 males and 2 females.
  • The patients primarily presented with a slowly enlarging painless deep dermal or subcutaneous mass.
  • The mass was located in the head and neck region in 3 cases, elbow in 1 case and foot in 1 case.
  • The patients underwent complete resection of the tumor, with no adjuvant chemotherapy and/or radiotherapy given.
  • During a period of follow up for 10 to 29 months, all of them had no recurrence or distant metastasis.
  • Gross examination showed that the tumor was well-circumscribed and had a grey-colored cut surface, with focal hemorrhagic cystic changes.
  • The average tumor dimension was 1.9 cm.
  • Histologically, the tumor was composed of histiocytoid or spindly cells arranged in nodular pattern.
  • Fibrillary neuropil-type intercellular material was identified in all cases and a fibrous pseudocapsule surrounded by lymphocytes and plasma cells was demonstrated in 3 cases.
  • Two cases were epithelial membrane antigen and CD99-positive.
  • CONCLUSIONS: AFH is a rare tumor of intermediate malignant potential.
  • Definitive diagnosis requires thorough histologic examination and clinical correlation.
  • Immunohistochemistry is also helpful for diagnosis and differential diagnosis.
  • Wide local excision with post-operative follow up is the main modality of treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aneurysm / metabolism. Aneurysm / pathology. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Chemotherapy, Adjuvant. Child. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Histiocytoma, Malignant Fibrous / pathology. Humans. Male. Radiotherapy, Adjuvant. Vimentin / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654123.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Desmin; 0 / Vimentin
  •  go-up   go-down


17. Cheng L, Foster SR, MacLennan GT, Lopez-Beltran A, Zhang S, Montironi R: Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum? J Urol; 2008 Oct;180(4):1235-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum?
  • PURPOSE: Inflammatory myofibroblastic tumor of the genitourinary tract is a spindled soft tissue lesion that is often mistaken for sarcoma.
  • These tumors have been described in numerous sites in the body and have been assigned many names.
  • The relationship between inflammatory myofibroblastic tumor and other morphologically similar entities has been a long-standing source of controversy.
  • We investigated whether inflammatory myofibroblastic tumors in adults and children are the same entity, and whether inflammatory myofibroblastic tumor is part of a biological spectrum that includes benign and malignant entities at opposite ends.
  • CONCLUSIONS: Inflammatory myofibroblastic tumor of the genitourinary tract should be considered a neoplasm of uncertain malignant potential, and routine surveillance and close clinical followup are recommended.
  • Aggressive therapy (radical cystectomy, radiation or chemotherapy) is unwarranted given the indolent and often benign clinical course for the majority of cases.
  • To understand the diagnostic and prognostic implications future emphasis should be placed on the link between genetic abnormalities, and clinical course, therapeutic response and ultimate outcome.
  • [MeSH-major] Carcinoma / pathology. Granuloma, Plasma Cell / pathology. Sarcoma / pathology. Urogenital Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Incidence. Neoplasm Staging. Prognosis. Risk Assessment. Ureteral Neoplasms / diagnosis. Ureteral Neoplasms / pathology. Urethral Neoplasms / diagnosis. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707729.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


18. Junginger T, Kettelhack C, Schönfelder M, Saeger HD, Rieske H, Krummenauer F, Hermanek P: [Therapeutic strategies in malignant soft tissue tumors. Results of the soft tissue tumor register study of the Surgical Oncology Working Group]. Chirurg; 2001 Feb;72(2):138-48
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategies in malignant soft tissue tumors. Results of the soft tissue tumor register study of the Surgical Oncology Working Group].
  • [Transliterated title] Therapeutische Strategien bei malignen Weichteiltumoren. Ergebnisse der Weichteiltumor-Registerstudie der CAO.
  • INTRODUCTION: This study, carried out by the Surgical Oncology Working Group (CAO) of the German Society for Surgery, was performed to analyse the strategies in the treatment of soft tissue sarcomas in adults.
  • METHODS: In a period of 19 months the data on 292 patients suffering from soft tissue sarcomas, treated in 99 surgical departments in Germany, were analysed prospectively.
  • A special questionnaire was developed including pretherapeutic biopsy, previous treatment, definitive surgical treatment, combined modality approach and histopathological results.
  • Limb-sparing treatment was performed in 96% of the extremity tumours.
  • In spite of less radical treatment in tumours of the trunk, additional radiotherapy was not more frequently performed.
  • CONCLUSION: To improve the quality in the treatment of soft tissue sarcomas it seems to be of great importance to avoid inadequate initial treatment (18%), to respect the rules of oncological surgery (tumour rupture in 7% of cases), to improve the histopathological examination (no R classification in 5-12%) and to develop guidelines for multimodality treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Nerve Sheath Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Germany. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / radiotherapy. Leiomyosarcoma / surgery. Liposarcoma / drug therapy. Liposarcoma / radiotherapy. Liposarcoma / surgery. Liposarcoma, Myxoid / drug therapy. Liposarcoma, Myxoid / radiotherapy. Liposarcoma, Myxoid / surgery. Lymph Node Excision. Male. Middle Aged. Prospective Studies. Radiotherapy, Adjuvant. Registries. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11253672.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Smith SE, Keshavjee S: Primary chest wall tumors. Thorac Surg Clin; 2010 Nov;20(4):495-507
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chest wall tumors.
  • The differential diagnosis of chest wall tumors is diverse, including both benign and malignant lesions (primary and malignant), local extension of adjacent disease, and local manifestations of infectious and inflammatory processes.
  • Primary chest wall tumors are best classified by their primary component: soft tissue or bone.
  • Work-up consists of a thorough history, physical examination and imaging to best assess location, size, composition, association with surrounding structures, and evidence of any soft tissue component.
  • Biopsies are often required, especially for soft tissue masses.
  • Treatment depends on histological subtype and location, but may include chemotherapy and radiotherapy in addition to surgical resection.
  • [MeSH-major] Bone Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Thoracic Neoplasms / surgery. Thoracic Wall
  • [MeSH-minor] Chondrosarcoma / surgery. Clavicle / surgery. Fibrous Dysplasia of Bone / surgery. Giant Cell Tumor of Bone / surgery. Histiocytosis, Langerhans-Cell / surgery. Humans. Osteochondroma / surgery. Reconstructive Surgical Procedures. Ribs / surgery. Sternum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20974433.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


20. Seok JY, Lee KG: Cytologic features of metastatic lymphoepithelial carcinoma in pleural fluid: a case report. Acta Cytol; 2009 Mar-Apr;53(2):215-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of metastatic lymphoepithelial carcinoma in pleural fluid: a case report.
  • BACKGROUND: Lymphoepithelial carcinoma of the salivary gland is a rare undifferentiated or poorly differentiated squamous cell carcinoma associated with abundant inmphocytes.
  • Only a handful of reports descibe the cytologic features of fine needle aspiration in lymphoepithelial carcinoma of the salivary gland and lymph nodes.
  • CASE: A 29-year-old man presented with a painless mass in his right parotid gland.
  • After the surgical specimen was evaluated, the mass was diagnosed as a lymphoepithelial carcinoma, which extended to the periglandular soft tissue with lymph node metastasis.
  • Despite radiation and chemotherapy, multiple mediastinal lymph node metastases, including in the right hilar lymph nodes, occurred.
  • Pulmonary atelectasis of the right upper lobe and a right pleural effusion developed.
  • Aspiration cytology of metastatic lymph nodes and pleural effusion cytology both demonstrated strongly cohesive clusters of tumor cells.
  • These cells had vesicular nuclei and prominent nucleoli admixed with benign lymphoid cells.
  • CONCLUSION: Pleural effusion cytopathology ofmetastatic lymphoepithelial carcinoma is similar to that of primary tumor fine needle aspiration.
  • Therefore, a specific diagnosis of lymphoepithelial carcinoma is possible on the basis of body fluid with these cytologic features.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Parotid Neoplasms / pathology. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Humans. Lymphatic Metastasis / pathology. Male. Pulmonary Atelectasis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365979.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Vered M, Allon I, Buchner A, Dayan D: Clinico-pathologic correlations of myofibroblastic tumors of the oral cavity. II. Myofibroma and myofibromatosis of the oral soft tissues. J Oral Pathol Med; 2007 May;36(5):304-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathologic correlations of myofibroblastic tumors of the oral cavity. II. Myofibroma and myofibromatosis of the oral soft tissues.
  • BACKGROUND: Myofibroma is a solitary benign tumor of myofibroblasts.
  • The clinico-pathologic correlations of myofibroma/myofibromatosis confined only to oral soft tissues were analyzed.
  • METHODS: In the English language literature, 41 myofibroma and 12 myofibromatosis cases involving the oral soft tissues were found.
  • RESULTS: Age at time of diagnosis of oral mucosa myofibroma ranged from birth to 70 years (mean 21.7 years), considerably higher than myofibroma in other parts of the body.
  • Male:female ratio was 1:1.6, contrary to the male predominance in other parts of the body.
  • Treatment was local excision, either complete (n = 13) or partial (n = 3), wide excision (n = 4), surgery, and chemotherapy (n = 1).
  • Myofibromatosis involving oral soft tissues was diagnosed at birth in nine (75%) patients, within the first year in two, and as a young adult in one.
  • Male:female ratio was 2:1.
  • Half the patients died of disseminated disease within a few days from birth, three were cured by partial or complete excision, and three experienced spontaneous regression.
  • CONCLUSIONS: Myofibroma should be included in the clinical differential diagnosis of masses of the oral soft tissues, especially in the tongue and buccal mucosa of children and adolescents.
  • Histological differential diagnosis includes benign and malignant spindle-shaped lesions.
  • Treatment of choice is local excision.
  • [MeSH-major] Lip Neoplasms / pathology. Mouth Mucosa / pathology. Myofibromatosis / pathology. Neoplasms, Muscle Tissue / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Infant. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Oral Pathol Med. 2008 Jan;37(1):62 [18154581.001]
  • (PMID = 17448141.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Number-of-references] 54
  •  go-up   go-down


22. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] WHO-Klassifikation der Hodentumoren.
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • This lesion is missed in germ cell tumors of childhood and in spermatocytic seminomas, both seem to have a histogenetic history rather different from the other germ cell in adults.
  • Seminoma with syncytiotrophoblastic cells is a variant which should not be confused with choriocarcinoma.
  • Spermatocytic seminomas are perfectly benign tumors but they become a life threatening disease when combined with sarcomas (new entity).
  • In the group of mature teratomas the "dermoid cyst" appears as a benign subtype mostly observed in children.
  • Unfortunately, however, the old term "teratoma with malignant transformation" was changed to "teratoma with malignant areas" in the 1998 classification.
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • "Large cell calcifying Sertoli cell tumour" has been recently described and can be sporadic or inherited.
  • This morphologically peculiar tumor can be part of the Swiss syndrome also called Carney's complex.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • The newly appearing "mixed germ cell--sex cord/gonadal stromal tumours, unclassified" has a histology similar to the well known gonadoblastomas.
  • In contrast to gonadoblastoma, however, these tumors occur in testes of genotypic and phenotypic normal males.
  • From the practical, diagnostic point of view the new classification does not contain dramatic changes.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.
  • [MeSH-major] Testicular Neoplasms / classification
  • [MeSH-minor] Humans. Male. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


23. López Almaraz R, Villafruela Alvarez C, Rodríguez Luis J, Doménech Martínez E: [Neonatal neoplasms: a single-centre experience]. An Pediatr (Barc); 2006 Dec;65(6):529-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neonatal neoplasms: a single-centre experience].
  • [Transliterated title] Neoplasias neonatales: experiencia de un centro.
  • INTRODUCTION: Malignant tumors are uncommon in the neonatal period and benign tumors may have malignant potential.
  • OBJECTIVES: To describe the neoplasms diagnosed and treated in newborns (</= 28 days of life) in the Hospital Universitario de Canarias and their association with congenital abnormalities and to evaluate prenatal diagnosis of these tumors.
  • PATIENTS AND METHODS: The medical records of patients with neoplasms diagnosed during the neonatal period in the previous 25 years in our hospital were retrospectively reviewed.
  • The variables analyzed were the percentage of neonatal neoplasms among the total number of cancer cases in children aged less than 14 years, their incidence among all the newborns in our hospital, sex, year of diagnosis, age at clinical diagnosis, the presence or absence of prenatal diagnosis, type of tumor (histologic diagnosis), association with syndromes or other congenital anomalies, treatment, and long-term outcome.
  • RESULTS: Of 260 neoplasms diagnosed in our unit from 1980, 16 (6.1 %) were diagnosed in the neonatal period.
  • The incidence of neonatal neoplasms was estimated to be 276.5 per million live births.
  • Males accounted for 43.8 % and females for 56.2 %, with a mean age at diagnosis of 5.5 days (range 1-28 days).
  • Five neonates (31.2 %) had a prenatal diagnosis, 60 % of which were made in the last 7 years of the study period.
  • Histologic diagnoses were neuroblastoma (n = 5; 31.2 %), teratoma/ germ cell tumor (n = 4; 25 %), soft tissue sarcoma (one fibrosarcoma of the thigh and two hemangiopericytoma of the back and heart; 18.8 %), and one case each of mesoblastic nephroma, cerebral tumor (ependymoblastoma), melanoma (associated with giant congenital melanocytic nevi), and acute leukemia (associated with Down syndrome).
  • Treatment consisted of surgery alone (n = 10; 62.5 %) and surgery plus chemotherapy (n = 5; 31.2 %); one patient received no treatment.
  • CONCLUSIONS: The neoplasms most frequently diagnosed in the neonatal period were solid tumors, mainly neuroblastoma and teratomas/germ cell tumors; 12.5 % were associated with syndromes or congenital anomalies.
  • In the last 7 years, the prenatal diagnosis of these entities has improved.
  • Most of the neoplasms responded to therapy, mainly surgery, and long-term outcome was favorable.
  • [MeSH-major] Neoplasms
  • [MeSH-minor] Female. Humans. Infant, Newborn. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Pediatr (Barc). 2007 Jul;67(1):85-6 [17663916.001]
  • (PMID = 17194321.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Reinecke P, Steckstor M, Schmitz M, Gabbert HE, Gerharz CD: Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart. Oncol Rep; 2004 Mar;11(3):641-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary malignant fibrous histiocytoma (MFH) of the heart is a rare and highly malignant soft tissue tumor, which is largely resistant to conventional chemotherapy and radiotherapy.
  • Therefore, we analyzed growth inhibitory effects of different chemotherapeutic agents and mechanisms of drug resistance in the recently established cell line MFH-H derived from a human primary cardiac MFH.
  • The expression and function of multidrug resistance-related proteins, i.e. the P-glycoprotein, the multidrug resistance-associated protein (MRP) and the lung resistance-related protein (LRP) were determined by FACScan and functional assays of cellular drug efflux.
  • The response of MFH-H to etoposide, vincristine and paclitaxel/Taxol could not be predicted by the expression and function of P-glycoprotein, MRP and LRP.
  • [MeSH-major] Alkaloids / therapeutic use. Drug Resistance, Multiple. Heart Neoplasms / drug therapy. Histiocytoma, Benign Fibrous / drug therapy. Plant Extracts / therapeutic use. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor. Cell Separation. Cell Survival. Cells, Cultured. Coloring Agents / pharmacology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Etoposide / pharmacology. Flow Cytometry. Humans. Inhibitory Concentration 50. P-Glycoprotein / metabolism. Paclitaxel / pharmacology. Phenotype. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Vault Ribonucleoprotein Particles / metabolism. Vincristine / pharmacology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14767515.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents, Phytogenic; 0 / Coloring Agents; 0 / P-Glycoprotein; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 298-93-1 / thiazolyl blue; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Veronesi G, Spaggiari L, Mazzarol G, De Pas M, Leo F, Solli P, Pastorino U: Huge malignant localized fibrous tumor of the pleura. J Cardiovasc Surg (Torino); 2000 Oct;41(5):781-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge malignant localized fibrous tumor of the pleura.
  • Localized fibrous tumor is an unfrequent mesenchymal neoplasm.
  • The malignant variant of the pleura is exceptional and differential diagnosis with the more frequent benign type or with other neoplasms such as soft tissue sarcoma and mesothelioma is rarely possible in a preoperative setting.
  • The best treatment of this disease is radical surgical resection.
  • No definitive data exist about the role of chemotherapy.
  • We report a case of a giant right intrathoracic mass whose preoperative diagnosis, from an open biopsy, was consistent with sarcoma and, in a second review, with fibrous tumor of the pleura without any indication about malignancy.
  • In consideration of the apparent local radicality we did not perform any adjuvant treatment.
  • Six months after the operation a wide local recurrence was evident and a systemic treatment with Ifosfamide and Adriamicina is still in progress.
  • Preoperative diagnosis of malignancy has an important role as a therapeutic strategy in management of fibrous tumours of the pleura.
  • When there is suspicion of a malignant form neoadjuvant chemotherapy can represent a further tool to control poorly differentiated and large tumors, and a wide surgical resection of the lesion must be performed.
  • [MeSH-major] Fibroma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pneumonectomy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149649.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


26. Pellegrino M, Vadrucci S, Tinelli A: [Angiomyofibroblastoma of the vulva: a rare but distinct entity. Case report and literature review]. Pathologica; 2007 Dec;99(6):438-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiomyofibroblastoma of the vulva: a rare but distinct entity. Case report and literature review].
  • Angiomyofibroblastoma is a benign vulvar tumour involving soft tissue that is characterized by alternating hypocellular and hypercellular areas of spindle stromal cells, admixed and aggregated around blood vessels.
  • It is important to recognize this entity as it shows benign behaviour with respect to other mesenchymal tumours of the vagina, which have a more aggressive behaviour.
  • [MeSH-major] Angiofibroma / pathology. Angiomyoma / pathology. Hemangioblastoma / pathology. Neoplasms, Second Primary / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Neoplasm Proteins / analysis. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416337.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  • [Number-of-references] 7
  •  go-up   go-down


27. Nakamura T, Kusuzaki K, Seto M, Matsumine A, Uchida A: Case report: recurrence of soft tissue MFH in bone due to minute intravenous tumor emboli detected by MRI. Oncol Rep; 2003 Nov-Dec;10(6):1957-60
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: recurrence of soft tissue MFH in bone due to minute intravenous tumor emboli detected by MRI.
  • We recently encountered a case with local recurrence of malignant fibrous histiocytoma (MFH) in the bone after wide resection, caused by minute intravenous tumor emboli which were retrospectively detected in MR imaging.
  • The patient was a 69-year-old woman who initially noticed a mass in her left thigh.
  • The tumor was diagnosed to be MFH, therefore a wide resection was performed; although the tumor was closely attached to the periosteum, it was not difficult to dissect the tumor subperiosteally from the cortex of the femur.
  • The patient received postoperative brachytherapy, but no chemotherapy.
  • Two years later, the tumor recurred with bony destruction of the femur.
  • We reviewed the pre-operative films obtained by various imaging modalities, as well as the histology of the primary tumor, and found minute intravenous tumor emboli in the MR imaging obtained before surgery.
  • Tumor emboli were also observed histologically in the small vessels of the surgically resected tumor.
  • Such intravenous tumor emboli have recently been implicated in the development of regional bone metastasis near the site of the primary lesion in cases of malignant soft tissue tumors.
  • Therefore, we concluded that the tumor recurrence in our case was caused by small tumor emboli invading the perforating veins of the femur.
  • It is therefore emphasized that MR images should be carefully reviewed for the presence of such intravenous tumor emboli before surgery in cases of high-grade malignant sarcomas.
  • As at the time of writing, our patient remains alive and disease-free, with no evidence of any local recurrence or distant metastasis after wide tumor resection for the recurrent tumor.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / metabolism. Magnetic Resonance Imaging / methods. Recurrence. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Aged. Brachytherapy. Disease-Free Survival. Female. Femur / pathology. Humans. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534725.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


28. Mevio E, Sbrocca M, Gorini E, Artesi L, Mullace M, Castelli A, Migliorini L: Malignant fibrous histiocytoma of the pharynx. Acta Otorhinolaryngol Belg; 2003;57(1):79-81
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life, but is relatively uncommon in the head and neck region.
  • That region has been reported to be the origin of malignant fibrous histiocytoma in 3-10% of cases.
  • Only one case of the tumor occurring in the pharynx has been reported.
  • Histologically it is sometimes hard to distinguish this tumor from some sarcomas and pleomorphic carcinomas.
  • The treatment of choice is a large surgical resection, while radiotherapy and chemotherapy are reserved for recurrences.
  • The authors present a case of oropharyngeal malignant fibrous histiocytoma.
  • Pharyngo-laryngoscopy revealed a mass of the left lateral wall of oro and hypopharynx.
  • CT scan examination showed a capsuled mass which displaced but not involved the neck neurovascular structures; there was no evidence of linphonodal involvement.
  • For more than 1 year postoperatively, there has been no evidence of the disease or metastasis.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / radiography. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiography
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12642957.001).
  • [ISSN] 0001-6497
  • [Journal-full-title] Acta oto-rhino-laryngologica Belgica
  • [ISO-abbreviation] Acta Otorhinolaryngol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


29. Lietman SA: Soft-tissue sarcomas: Overview of management, with a focus on surgical treatment considerations. Cleve Clin J Med; 2010 Mar;77 Suppl 1:S13-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas: Overview of management, with a focus on surgical treatment considerations.
  • Patients with soft-tissue sarcomas generally present with a mass that is increasing in size; the presence or absence of pain is not typically predictive of malignancy.
  • While magnetic resonance imaging (MRI) can identify a few soft-tissue lesion types as benign, diagnosis of most lesions requires a careful biopsy, preferably performed by or in consultation with the surgeon who would do an eventual resection.
  • If biopsy confirms a diagnosis of sarcoma, MRI-guided surgical resection with a wide margin is the mainstay of treatment.
  • Neoadjuvant radiation therapy and chemotherapy have not been of proven benefit in well-controlled studies but are frequently used as adjuncts.
  • Resections with wide margins are generally associated with a low (< 10%) risk of recurrence.
  • [MeSH-minor] Biopsy / methods. Humans. Magnetic Resonance Imaging. Risk Factors. Sentinel Lymph Node Biopsy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179181.001).
  • [ISSN] 1939-2869
  • [Journal-full-title] Cleveland Clinic journal of medicine
  • [ISO-abbreviation] Cleve Clin J Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


30. Rodríguez-Velasco A, Fermán-Cano F, Cerecedo-Díaz F: Rare tumor of the tongue in a child: alveolar soft part sarcoma. Pediatr Dev Pathol; 2009 Mar-Apr;12(2):147-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare tumor of the tongue in a child: alveolar soft part sarcoma.
  • Alveolar soft part sarcoma (ASPS) is a rare, malignant tumor of uncertain histogenesis that has no benign counterpart.
  • The neoplasm occurs most frequently in female adolescents and young adults, where it arises predominantly in the extremities.
  • The primary therapeutic option is a complete surgical excision.
  • Because of the indolent growth and lack of pain associated with the mass, 20% of patients have metastases at the time of initial diagnosis.
  • Median survival time reported for all sites of the body is 79 months.
  • The utility of adjuvant chemotherapy or radiation therapy in children is open to question.
  • Only 10 cases of ASPS occurring in the tongues of children younger than 5 years of age were indexed by MEDLINE between 1952 and 2006.
  • Here, we describe the 1st case consistent with typical ASPS of the tongue in 15 years at our hospital.
  • The patient is a 2-year-old girl who has been disease-free for 32 months.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Child, Preschool. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Disease-Free Survival. Female. Humans. Vimentin / analysis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630993.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vimentin; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  •  go-up   go-down


31. Fang Z, Matsumoto S, Ae K, Kawaguchi N, Yoshikawa H, Ueda T, Ishii T, Araki N, Kito M: Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan. J Orthop Sci; 2004;9(3):242-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan.
  • Radiation therapy (RT) is commonly used to treat malignant tumors, but it leads to side effects and complications.
  • Postradiation sarcomas developing from a previously irradiated area are especially vicious to deal with, though their occurrence is rare.
  • This article focuses on the clinical manifestations, pathological characteristics, and therapeutic effects concerning postradiation soft tissue sarcomas (PRSTSs).
  • A series of 14 PRSTSs treated between 1979 and 2000 in five hospitals in Japan were analyzed.
  • Their histological types were malignant fibrous histiocytoma (eight cases), extraskeletal osteosarcoma (four cases), fibrosarcoma (one case), and leiomyosarcoma (one case).
  • The primary diagnoses, RT history, latent period, and outcome of treatment were studied retrospectively.
  • The original tumors included uterine cancer (seven cases), breast cancer (four cases), synovial sarcoma (one case), squamous cell carcinoma (one case), and Hodgkin's disease (one case).
  • There were 13 women and 1 man, with ages ranging from 23 to 77 years (mean 58 years) at the time of the appearance of the PRSTS.
  • RT doses ranged from 48 to 91 Gy (mean 62 Gy).
  • Of the 10 patients whose tumors were removed with a wide margin, one had a local recurrence; 3 cases were performed with a marginal margin and all 3 had a local recurrence.
  • One of three who underwent RT and one of five who underwent chemotherapy (CT) responded.
  • Of the 14 patients, 6 (42.9 %) survived continuously disease free, 2 (14.3%) died from other causes, 2 (14.3%) has an unknown outcome, and 4 (28.6 %) died of the disease during the follow-up period of 16-36 months (mean 24 months).
  • The deaths due to other causes included an esophageal cancer and a wound infection.
  • The prognosis of the PRSTS patients was not poor if the tumor could be removed with a wide surgical margin.
  • Because adjuvant therapies including RT and CT had a poor effect on PRSTSs, the primary treatment of PRSTSs should be radical resection with a wide margin.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / radiotherapy. Female. Histiocytoma, Benign Fibrous / etiology. Histiocytoma, Benign Fibrous / surgery. Humans. Japan. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Uterine Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] The Japanese Orthopaedic Association
  • (PMID = 15168177.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


32. Shinozaki T, Kato K, Watanabe H, Yanagawa T, Ahmed AR, Takagishi K: Discriminant analysis of prognostic factors for malignant fibrous histiocytoma in soft tissue. J Orthop Sci; 2001;6(4):339-42
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discriminant analysis of prognostic factors for malignant fibrous histiocytoma in soft tissue.
  • We prospectively followed 32 patients with soft-tissue malignant fibrous histiocytoma (MFH).
  • Parameters were age; sex; tumor size, location, and depth; operative method; chemotherapy; radiotherapy; and histology.
  • Patients with recurrence or metastases due to MFH within 6 months after the initial operation were separated from those without these characteristics by discriminant analysis with statistically significant difference.
  • The order of influential functions was histology, depth of tumor, operative method, and sex.
  • Male patients with deep-seated storiform-pleomorphic type MFH, receiving less comprehensive surgery, had the greatest risk of local recurrence or early metastases.
  • We have to pay particular attention to patients with these factors and perform adequate surgery, because local recurrence and metastases were found to be closely related, and to have a great influence on the prognosis of this disease.
  • Discriminant analysis to separate patients with MFH recurrence or metastases within 6 months after the initial operation from those without these characteristics is worthwhile for prognostic assessment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Discriminant Analysis. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Prospective Studies. Retrospective Studies. Risk Factors. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11479763.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


33. Garner HW, Kransdorf MJ, Bancroft LW, Peterson JJ, Berquist TH, Murphey MD: Benign and malignant soft-tissue tumors: posttreatment MR imaging. Radiographics; 2009 Jan-Feb;29(1):119-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and malignant soft-tissue tumors: posttreatment MR imaging.
  • Soft-tissue sarcoma requires aggressive treatment, often with a combination of radiation therapy, chemotherapy, and surgical resection.
  • Even after multimodality treatment, local recurrence is common, and regular follow-up imaging at short intervals is required.
  • Interpretation of posttreatment magnetic resonance (MR) images may be complicated by changes in the surgical bed or treatment field.
  • The challenge of distinguishing posttreatment change from recurrent tumor may be minimized by using an organized, systematic approach to imaging, with emphasis on the patient's clinical and surgical history and a review of pretreatment images.
  • Common changes that result from radiation therapy include soft-tissue trabeculation, increased fatty marrow, and focal marrow abnormalities.
  • Rarely, radiation-induced malignancies may develop within the treatment field.
  • Chemotherapy also influences posttreatment imaging appearance.
  • Occasionally, it causes a substantial increase in tumor size that is a result of chemotherapy-induced hemorrhage.
  • Although myocutaneous flaps used in reconstructive surgery may mimic a mass, they demonstrate time-dependent changes in size, signal intensity, and enhancement on MR images.
  • Recurrent tumor is characterized by the presence of a discrete nodule or mass with signal characteristics that typically mirror those of the original tumor.
  • MR imaging sequences such as unenhanced T1-weighted fat-suppressed and gradient-echo sequences may help differentiate posttreatment hemorrhage from local tumor recurrence.
  • A consistent imaging approach combined with a detailed knowledge of the patient's history, familiarity with pretreatment images, and an understanding of the various posttreatment changes enables optimal monitoring of the treatment bed and maximizes accuracy in the detection of recurrence.
  • [MeSH-major] Image Enhancement / methods. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Postoperative Care / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • (PMID = 19168840.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Moser A, Hoffmann KM, Walch C, Sovinz P, Lackner H, Schwinger W, Benesch M, Fritz G, Urban C: Intracranial reparative giant cell granuloma secondary to cholesteatoma in a 15-year-old girl. J Pediatr Hematol Oncol; 2008 Dec;30(12):935-7
Hazardous Substances Data Bank. DICLOFENAC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 15-year-old girl presented with pain in the right ear and acute onset of total peripheral facial nerve palsy.
  • A first biopsy led to the diagnosis of intracranial giant cell reparative granuloma (GCRG), a rare benign tumor of the bone or soft tissue that can show expansive growth.
  • Facial nerve palsy responded to treatment with diclofenac and physiotherapy, however, the intracranial lesion progressed at follow-up.
  • [MeSH-minor] Adolescent. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Diclofenac / therapeutic use. Facial Paralysis / drug therapy. Facial Paralysis / etiology. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cholesteatoma.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131785.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


35. Saleh H, Kapadia R: Aspiration biopsy cytology of extraabdominal desmoid tumor concurrently occurring in a patient with tumoral calcinosis. Diagn Cytopathol; 2008 Sep;36(9):624-7
Genetic Alliance. consumer health - Desmoid Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspiration biopsy cytology of extraabdominal desmoid tumor concurrently occurring in a patient with tumoral calcinosis.
  • Extraabdominal fibromatosis or desmoid tumor (DT) is a slow growing locally aggressive soft tissue tumor that can occur anywhere in the body.
  • We report the aspiration biopsy cytology features of a case of DT of the right neck area in a 35-year-old man who had a long standing history of tumoral calcinosis.
  • The aspirate was interpreted as "benign spindle cell lesion" and confirmed as DT on histologic examination of the resected mass.
  • We discuss the possible differential diagnoses of other benign or malignant lesions on fine-needle aspiration (FNA) biopsy and especially discuss the aspiration cytology features of DT compared with those of tumoral calcinosis.
  • We also discuss the value of immunohistochemical markers that help in differentiating DT from other entities.
  • [MeSH-major] Calcinosis / complications. Fibromatosis, Abdominal / complications. Fibromatosis, Abdominal / pathology. Soft Tissue Neoplasms / complications. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Cell Nucleus / pathology. Humans. Male. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677759.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta Catenin
  •  go-up   go-down


36. Rossi S, Fletcher CD: Angiosarcoma arising in hemangioma/vascular malformation: report of four cases and review of the literature. Am J Surg Pathol; 2002 Oct;26(10):1319-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant change in a benign vascular tumor is exceedingly rare, and there have been only five previously reported convincing cases.
  • All patients were in the 6th or 7th decade of life (two female, two male).
  • MRI disclosed the presence of two separate soft tissue masses in both thighs in one patient.
  • Three tumors were located in the lower extremities (thigh and buttock), one in the retroperitoneum, and one in the parotid region.
  • Three patients were treated by marginal excision; in one case only a biopsy was performed.
  • Radiotherapy/chemotherapy was given in all cases.
  • Two patients were disease free 2 and 14 months after surgery and two developed metastases.
  • Grossly, the tumors were described as frankly hemorrhagic masses or as firm, whitish areas with hemorrhagic nodules and were centered in skeletal muscle in three cases.
  • In three cases the benign and the malignant components were variably intermixed, whereas in one case the HVM was mainly located at the edge of the malignant tumor.
  • The benign component showed features of an arteriovenous hemangioma (three cases) or intramuscular capillary hemangioma.
  • AS showed epithelioid morphology in three cases and a well-differentiated dissecting pattern in one case.
  • The two anatomically separate masses excised from one patient appeared almost identical.
  • [MeSH-major] Hemangioma / pathology. Hemangiosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic. Disease-Free Survival. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12360047.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Merriman DJ, Deavers MT, Czerniak BA, Lin PP: Massive desmoplastic fibroblastoma with scapular invasion. Orthopedics; 2010 Aug;33(8)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Desmoplastic fibroblastoma is a rare benign tumor usually associated with a favorable outcome.
  • The tumor is characterized by fibroblastic cells that are sparsely distributed in a collagenous and fibromyxoid background.
  • The growth of this tumor is generally indolent, and most tumors are small, subcutaneous lesions.
  • Invasion and destruction of bone are distinctly uncommon features.This article describes an unusual case of desmoplastic fibroblastoma that presented with a massive 23-cm tumor.
  • The tumor was also unique for its infiltration and destruction of the scapula.
  • The aggressive clinical features prompted the original physicians to administer chemotherapy, but the tumor exhibited no response to systemic treatment.
  • The patient eventually underwent limb-sparing surgery at our hospital, which included en bloc resection, complete scapulectomy, and osteoarticular allograft replacement.
  • The invasiveness of the tumor and its large size are distinctly unusual for desmoplastic fibroblastomas.
  • Following surgical excision, the patient has remained continuously disease free for >5 years, which is in keeping with the intrinsically benign nature of the tumor.
  • This case demonstrates that desmoplastic fibroblastoma can occasionally reach an enormous size and may exhibit invasive characteristics, but this does not necessarily portend subsequent recurrence of disease.
  • [MeSH-major] Fibroma, Desmoplastic / pathology. Scapula / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • [CommentIn] Orthopedics. 2011 Nov;34(11):836-7; author reply 837 [22050246.001]
  • (PMID = 20704102.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Woźniak AW, Nowaczyk MT, Osmola K, Golusinski W: Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature. Eur Arch Otorhinolaryngol; 2010 Jun;267(6):845-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature.
  • Benign osteoblastoma is a rarely seen tumor of the facial bones.
  • The authors present a case of a 30-year-old man with a tumor of the mandibular body and ramus.
  • The histopathological diagnosis was one of osteoblastoma.
  • Postoperative recurrence with soft tissue infiltration suggested an osteosarcoma radiologically, but the histological examination again revealed the presence of an osteoblastoma.
  • A second recurrence occured in the pharyngo-glossal region and this time the tumor was histologically diagnosed as an osteoblastoma, but with foci of well-differentiated osteosarcoma.
  • The patient was given a course of radiotherapy, but clinical and radiological examination 8 months later revealed lung metastases and chemotherapy was started.
  • While osteoblastomas are rare, and their sarcomatous change even rarer, our experience with this case lead us to suggest that a therapeutic preventative approach, involving both chemotherapy and total excision of the tumor, is the regime to adopt with osteoblastomas which involve soft tissues and have radiological features suggesting malignancy.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Mandibular Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Osteoblastoma / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Mandible / pathology. Mandible / surgery. Radiography, Panoramic. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Spine J. 1998;7(3):246-8 [9684960.001]
  • [Cites] J Clin Pathol. 1993 Nov;46(11):1024-9 [8254089.001]
  • [Cites] Neurosurg Rev. 1997;20(1):51-4 [9085288.001]
  • [Cites] Histopathology. 1997 Aug;31(2):196-200 [9279574.001]
  • [Cites] Med Pediatr Oncol. 1997 Apr;28(4):305-9 [9078333.001]
  • [Cites] Skeletal Radiol. 1994 Oct;23 (7):509-12 [7824976.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):138-42 [2045899.001]
  • [Cites] Gen Diagn Pathol. 1996 May;141(5-6):377-92 [8780939.001]
  • [Cites] Eur J Radiol. 1998 May;27 Suppl 1:S91-7 [9652508.001]
  • [Cites] Skeletal Radiol. 1994 Nov;23 (8):656-9 [7886478.001]
  • [Cites] Aktuelle Radiol. 1996 Nov;6(6):338-40 [9081408.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):416-26 [3855268.001]
  • [Cites] J Comput Assist Tomogr. 1996 Jan-Feb;20(1):116-8 [8576460.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):117-34 [8119712.001]
  • [Cites] Chirurg. 2002 Dec;73(12 ):1181-90 [12491047.001]
  • [Cites] Arq Neuropsiquiatr. 1998 Jun;56(2):292-5 [9698743.001]
  • [Cites] J Laryngol Otol. 1997 Sep;111(9):865-8 [9373556.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jan;52(1):86-90 [8263651.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Feb;18(2):324-6 [9111670.001]
  • [Cites] Surg Neurol. 1998 Mar;49(3):274-7 [9508114.001]
  • (PMID = 20012077.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


39. Kawamoto T, Akisue T, Marui T, Nakatani T, Hitora T, Fujita I, Kurosaka M, Yamamoto T: Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines. Anticancer Res; 2004 Sep-Oct;24(5A):2675-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
  • BACKGROUND: Malignant fibrous histiocytoma (MFH) is one of the most common high-grade sarcomas in bone and soft tissue and, due to its chemo-resistance, the prognosis of the disease is poor.
  • ST1571 is a tyrosine kinase inhibitor that was initially developed as a BCR/ABL inhibitor for chronic myeloid leukemia patients.
  • STI571 also selectively inhibits platelet-derived growth factor receptors (PDGFRs) and c-kit.
  • We examined the expression of PDGFRs and c-kit in human MFH cell lines, and the effect of STI571 on cell proliferation.
  • MATERIALS AND METHODS: Four human MFH cell lines (TNMY1, GBS-1, Nara-F and Nara-H) were used. mRNA expression of the receptor tyrosine kinases (PDGFRs and c-kit) was analyzed using reverse transcription-polymerase chain reaction, and the inhibitory effect of STI571 on cell proliferation was analyzed using the MTS assay technique.
  • RESULTS: PDGFRalpha mRNA was expressed in TNMY1 and GBS-1, and PDGFRbeta and c-kit mRNAs were expressed in TNMY1, GBS-1 and Nara-F.
  • STI571 inhibited cell proliferation of TNMY1, GBS-1 and Nara-F in a dose- and time-dependent manner, but cell proliferation of Nara-H was not inhibited by ST1571 at concentrations of 10 microM or less.
  • CONCLUSION: STI571 significantly inhibited proliferation of the three human MFH cell lines that expressed mRNAs of target receptor tyrosine kinases.
  • The inhibitory effect of ST1571 on cell proliferation in these three cell lines might be due to decreased tyrosine kinase activity.
  • STI571 might be a potent chemotherapeutic agent for human MFHs.
  • [MeSH-major] Histiocytoma, Benign Fibrous / drug therapy. Piperazines / pharmacology. Protease Inhibitors / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Benzamides. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Imatinib Mesylate. Proto-Oncogene Proteins c-kit / biosynthesis. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / genetics

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15517872.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protease Inhibitors; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


40. Belal A, Kandil A, Allam A, Khafaga Y, El-Husseiny G, El-Enbaby A, Memon M, Younge D, Moreau P, Gray A, Schultz H: Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol; 2002 Feb;25(1):16-22
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this report is to assess the prognostic factors that could influence management and clinical outcome of malignant fibrous histiocytoma (MFH) of soft tissues.
  • Between 1975 and 1998, 109 patients diagnosed with MFH of the soft tissues, seen at King Faisal Specialist Hospital and Research Center, have been reviewed.
  • Seven patients (6%) had regional nodal disease and 10 other patients (9%) with distant metastases were excluded from survival analysis.
  • The remaining 92 patients had localized disease and had surgery as the primary treatment modality with or without radiotherapy and/or chemotherapy.
  • The 5- and 10-year relapse-free survival (RFS) rates were 39% and 36%, respectively.
  • Isolated local recurrence occurred in 20 patients (22%), isolated metastatic disease without local recurrence in 9 patients (10%), and combined local and metastatic disease occurred in 20 patients (22%).
  • The overall 5- and 10-year overall survival (OS) rates were 50% and 43%, respectively.
  • On multivariate analysis, tumor size and radiation dose were significant factors for RFS (p = 0.04 and 0.0005, respectively).
  • In terms of OS, size, histologic grade, and surgical margins were significant factors on multivariate analysis (p = 0.001.
  • Complete surgical resection at the time of primary tumor presentation is likely to afford the best chance for RFS and OS.
  • Radiation therapy plays an important role, in combination with surgery for better local control, particularly in high-grade lesions, and in cases with positive surgical margins after wide complete gross excision.
  • The role of adjuvant chemotherapy remains investigational.
  • [MeSH-major] Histiocytoma, Benign Fibrous. Soft Tissue Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11823689.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Ramirez RN, Otsuka NY, Apel DM, Bowen RE: Desmoid tumor in the pediatric population: a report of two cases. J Pediatr Orthop B; 2009 May;18(3):141-4
Genetic Alliance. consumer health - Desmoid Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoid tumor in the pediatric population: a report of two cases.
  • Desmoid tumors are benign tumors that cause considerable morbidity and are prone to recurrence.
  • They tend to extensively infiltrate surrounding tissues, complicating the treatment.
  • We present the report of two cases of desmoid tumor in the pediatric population.
  • The first patient had tumor that necessitated removal of most of the anterior compartment of his leg.
  • The tumor in the second case was intimately involved with neurovascular structures and, therefore adjuvant treatment including chemotherapy and repeat surgery was necessary.
  • [MeSH-major] Fibromatosis, Aggressive / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Infant. Leg / surgery. Male. Neoplasm Recurrence, Local. Tendon Transfer. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322113.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Adamson DC, Cummings TJ, Friedman AH: Malignant peripheral nerve sheath tumor of the spine after radiation therapy for Hodgkin's lymphoma. Clin Neuropathol; 2004 Sep-Oct;23(5):245-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of the spine after radiation therapy for Hodgkin's lymphoma.
  • We report the development of a malignant peripheral nerve sheath tumor (MPNST) in 2 patients after irradiation for Hodgkin's lymphoma.
  • Clinicians should be aware of this uncommon, but important fatal complication of radiation therapy.
  • The first case is a 37-year-old man who was diagnosed with nodular sclerosing (NS) Hodgkin's lymphoma and underwent successful mantle radiation.
  • He presented to our neurosurgery service with a left C6 radiculopathy 6 years later.
  • The second case is a 30-year-old female diagnosed with NS Hodgkin's lymphoma.
  • She did well with extensive radiotherapy until 5 years later when she developed severe right arm and chest pain secondary to recurrent lymphoma.
  • After aggressive radio- and chemotherapy, she presented to the neurosurgery service with a right Horner's syndrome, right C6 radiculopathy, and weakness of her right triceps and wrist extensors.
  • Both patients obtained magnetic resonance imaging revealing intradural extramedullary cervical nerve root associated mass lesions.
  • Two years after radiation therapy for his Hodgkin's lymphoma, the first patient underwent a C6 laminectomy at an outside institution for resection of a benign neurofibroma.
  • Four years later, he underwent a posterior C5-7 laminectomy with lateral mass plate fusion and partial excision of a recurrent mass diagnosed as a MPNST.
  • The second patient underwent a C5-6 hemilaminectomy and partial resection of a tumor also pathologically consistent with MPNST.
  • We present 2 case reports of patients who developed neurofibrosarcomatous tumors with malignant transformation after undergoing radiation therapy for Hodgkin's lymphoma.
  • Numerous cases of soft tissue tumors have been described to arise in areas of prior radiation therapy; however, there have been rare reports of de novo MPNST after radiation therapy, especially in the setting of Hodgkin's lymphoma.
  • Postirradiation MPNST should be considered in the differential diagnosis of a painful, enlarging mass in a previously irradiated area.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Lymphatic Irradiation / adverse effects. Neoplasms, Radiation-Induced / pathology. Nerve Sheath Neoplasms / etiology. Spinal Neoplasms / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male


43. Albert A, Cruz O, Montaner A, Vela A, Badosa J, Castañón M, Morales L: [Congenital solid tumors. A thirteen-year review]. Cir Pediatr; 2004 Jul;17(3):133-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumores sólidos congénitos. Revisión de 13 años.
  • Tumors diagnosed during the first month of life are infrequent: 0.5 to 2% of all childhood neoplasms.
  • This is an interesting group of tumors because their type, relative incidence, natural history and response to treatment differ from those seen in older children.
  • Neuroblastoma was the commonest tumor (10 cases, 37%), of which 4 were stage I, 4 stage IV-S and 2 stage III.
  • There were 8 teratomas (3 sacrocoxigeal, 1 retroperitoneal, 1 in the CNS, 1 orbitary and two oronasal), two hepatic tumors (1 hepatoblastoma, 1 hemangioendothelioma, two CNS tumors, two giant nevus (one on a hamartoma), and one each Wilms tumor, infantile fibrosarcoma and myofibroblastic tumor.
  • Treatment was surgical resection alone in 17 cases (68%) and surgery + chemotherapy in 8 (32%) (5 neuroblastomas, one CNS tumor, one Wilms tumor and one presacral teratoma who developed a yolk sac tumor); 3 patients died (11%): one at surgery, one of tumoural airway obstruction at birth and one with craniopharyngioma.
  • Among the 14 tumors that were initially not malignant, two can be locally agressive, one was an immature teratoma, the giant nevus with hamartoma developed in situ melanoma, the other nevus had meningeal melanosis with hydrocephalus, and one mature presacral teratoma developed a yolk sac tumor.
  • CONCLUSIONS: Diagnosis of congenital tumors is performed earlier in recent years due to the wide use of prenatal ultrasound.
  • Their natural history is more benign than in other age groups, except for CNS tumors and very large or obstructing tumors.
  • The histological patern is not determinant of the outcome.
  • Complete surgical excision is the treatment of choice, most cases not need adjuvant chemotherapy.
  • We ought to pass this message on to our colleagues in prenatal diagnosis, so parents get reliable information.
  • [MeSH-major] Central Nervous System Neoplasms / congenital. Kidney Neoplasms / congenital. Liver Neoplasms / congenital. Neuroblastoma / congenital. Skin Neoplasms / congenital. Soft Tissue Neoplasms / congenital. Teratoma / congenital. Wilms Tumor / congenital
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local. Postoperative Complications. Pregnancy. Prenatal Diagnosis. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503950.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


44. Jarmundowicz W, Jabłoński P, Załuski R: [Brachial plexus tumors--neurosurgical treatment]. Neurol Neurochir Pol; 2002 Sep-Oct;36(5):925-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brachial plexus tumors--neurosurgical treatment].
  • Tumours of the brachial plexus according to present classification are included to soft tissue tumours.
  • Therefore the aim of the study was to present our experience in the surgical treatment of tumours of the brachial plexus basing on the material of 5 cases treated in the years 1997-2001.
  • There were 4 males and 1 female, age from 17 to 58 years old.
  • In 3 cases tumours of the brachial plexus invaded the spinal canal through the intervertebral foramen and caused spinal cord compression (type A).
  • In 2 cases tumours involved only plexus elements (type B).
  • In 2 cases tumours were associated with neurofibromatosis type II.
  • In case of schwannomas and neurofibromas the surgical removal was radical without impairment of brachial plexus function.
  • In case of a giant schwannoma malignum tumor, which caused flaccid paresis and symptoms of insufficient blood, supply with severe pain in the upper limb radical extirpation was also possible.
  • In type A tumours in the first stage intraspinal part of the tumor was removed.
  • The result of treatment of benign tumours was very good with complete function recovery of the upper limb, pain disappearance and no symptoms of recurrence in the long postoperative period.
  • In case of malignant schwannoma in the early postoperative period both pain and symptoms of blood supply disturbances completely disappeared.
  • The patient died 12 months after the operation because of tumor dissemination.
  • Benign tumours of the brachial plexus can be effectively surgically treated using microsurgical techniques and, if necessary, nerve grafting.
  • In case of malignant tumours many authors also recommend surgery with optimal sparing of the brachial plexus function and subsequent radio and chemotherapy.
  • Low number A few cases in our series makes impossible to draw any epidemiological conclusions.
  • [MeSH-major] Brachial Plexus / surgery. Neurilemmoma / surgery. Neurofibroma / surgery. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12523117.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


45. Manili M, Fredella N, Santori FS: Shoulder prosthesis in reconstruction of the scapulohumeral girdle after wide resection to treat malignant neoformation of the proximal humerus. Chir Organi Mov; 2002 Jan-Mar;87(1):25-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Progress in preoperative chemotherapy and radiation therapy, both intra- and postoperative, has in time allowed for an increase in indications for shoulder implant surgery in malignant tumors, thus drastically reducing the number of amputations.
  • The use of prostheses, particularly those of the more recent generation, respond to the needs to overcome the limits of loss of movement, as long as good anatomical reconstruction of the soft tissues, the premise for good functional and cosmetic recovery, is also possible.
  • This type of prosthesis has surpassed custom made prostheses in terms of simplicity, adaptability and economy.
  • The main problem in reconstruction with a prosthesis is the quantity of residual muscular tissue (deltoideus, extrarotators) and the stabilization system of the same to the prosthesis in order to avoid dislocation, which constitutes the main complication.
  • It is the purpose of this study to present the clinical and functional results obtained in 23 implants carried out for primary malignant neoformation of the upper limb.
  • The implants studied were of three types (custom made, modular in Cr-Co-Mb and Ti-Al-Va).
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Histiocytoma, Benign Fibrous / surgery. Humerus / surgery. Joint Prosthesis. Sarcoma / surgery. Shoulder Joint / surgery
  • [MeSH-minor] Arthrodesis. Chondrosarcoma / surgery. Follow-Up Studies. Humans. Osteosarcoma / surgery. Prosthesis Failure. Sarcoma, Ewing / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12198947.001).
  • [ISSN] 0009-4749
  • [Journal-full-title] La Chirurgia degli organi di movimento
  • [ISO-abbreviation] Chir Organi Mov
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Schlott T, Taubert H, Fayyazi A, Schweyer S, Bartel F, Korabiowska M, Brinck U: Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide. Anticancer Res; 2004 Nov-Dec;24(6):3819-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide.
  • Soft tissue sarcomas frequently carry p53 mutations reducing chemotherapeutical response.
  • Especially malignant fibrous histiocytoma (MFH) reveals a reduced ifosfamide (IF) chemosensitivity when compared to other sarcoma entities.
  • The aim was to identify candidate genes possibly involved in the anti-apoptotic response of p53-deficient MFH cells during chemotherapy.
  • PCR, real-time RT-PCR and confocal laser scanning microscopy were applied on primary cultures of MFH cells containing defective p53 genes.
  • In contrast, the other proteins analyzed were not detectable.
  • These effects were neither observed in the non-treated culture nor in cultures completely inducing spontaneous apoptosis.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / genetics. Ifosfamide / pharmacology. Tumor Suppressor Protein p53 / deficiency
  • [MeSH-minor] Actins / biosynthesis. Actins / genetics. Alternative Splicing / drug effects. Caspase 3. Caspases / metabolism. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cyclin-Dependent Kinases / biosynthesis. Cyclin-Dependent Kinases / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Genes, Tumor Suppressor. Humans. Nuclear Proteins / biosynthesis. Nuclear Proteins / genetics. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-mdm2. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retinoblastoma Protein / biosynthesis. Retinoblastoma Protein / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Tumor Suppressor Protein p14ARF / biosynthesis. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736417.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / Antineoplastic Agents, Alkylating; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


47. Lehnhardt M, Daigeler A, Homann HH, Hauser J, Langer S, Steinsträsser L, Soimaru C, Puls A, Steinau HU: [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg; 2009 Apr;80(4):341-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases].
  • [Transliterated title] Die Bedeutung von Referenzzentren in Diagnose und Therapie von Weichgewebssarkomen der Extremitäten. Auswertung von 603 Fällen.
  • Correct histopathologic diagnosis is essential for adequate treatment of soft tissue sarcomas.
  • Due to the disorder's rarity, multitude of subgroups, sometimes varying histopathologic appearance, and occasionally inadequate biopsy specimens, diagnosis and grading are challenging.
  • The records of 603 patients with soft tissue tumors of the extremities were reviewed concerning mismatches in primary and definite diagnoses relating to entity, evaluation of primary or recurrent tumor specimens, and the diagnosing pathology institution.
  • In the eight most frequent sarcoma types, malignant peripheral nerve sheath tumors and leiomyosarcoma had the highest rates of false primary diagnosis, 78.4% and 74.2% of cases, respectively.
  • For optimal treatment of soft tissue sarcomas, we suggest obtaining expert second opinion to ensure adequate surgical therapy and precise indications for radiation and chemotherapy.
  • [MeSH-major] Cancer Care Facilities. Extremities / surgery. Hospitals, Special. Hospitals, University. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diagnostic Errors. Female. Germany. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / diagnosis. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neoplasm Staging. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery. Radiotherapy, Adjuvant. Referral and Consultation. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cancer Treat Res. 2004;120:43-63 [15217217.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):404-6 [3179848.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):48-61 [9990113.001]
  • [Cites] Curr Top Pathol. 1995;89:123-51 [7882706.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):451-62 [15509479.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):77-86 [15188669.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):212-9 [10613171.001]
  • [Cites] Bull Cancer. 2001 Aug;88(8):765-73 [11578945.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):305-9 [17254531.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):111-5 [11823981.001]
  • [Cites] Chirurg. 2007 Jan;78(1):62-4 [16786340.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 [11856592.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):237-46 [15056054.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):329-35 [10989631.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • (PMID = 18523742.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement